Dimed S.A. Distribuidora de Medicamentos (BVMF:PNVL3)

Brazil · Delayed Price · Currency is BRL

13.25

-0.23 (-1.71%)

Apr 28, 2026, 5:06 PM GMT-3

46.57% (1Y)

Market Cap	1.97B
Revenue (ttm)	5.51B
Net Income (ttm)	124.61M
Shares Out	148.68M
EPS (ttm)	0.83
PE Ratio	15.96
Forward PE	11.52
Dividend	0.34 (2.54%)
Ex-Dividend Date	Mar 27, 2026

Volume	392,700
Average Volume	747,675
Open	13.48
Previous Close	13.48
Day's Range	13.14 - 13.48
52-Week Range	8.06 - 16.57
Beta	0.55
RSI	32.88
Earnings Date	May 14, 2026

About BVMF:PNVL3

Dimed S.A. Distribuidora de Medicamentos sells medicines, perfumeries, personal hygiene and beauty products, cosmetics and dermocosmetics in Brazil. It sells its products through physical stores in retail industry. Dimed S.A. Distribuidora de Medicamentos was founded in 1920 and is headquartered in Eldorado do Sul, Brazil. [Read more]

Industry Drug Manufacturers - General

Sector Healthcare

Founded 1920

Employees 11,282

Stock Exchange Brazil Stock Exchange

Ticker Symbol PNVL3

Full Company Profile

Financial Performance

In 2025, BVMF:PNVL3's revenue was 5.51 billion, an increase of 11.53% compared to the previous year's 4.94 billion. Earnings were 124.61 million, an increase of 18.10%.

Financial Statements

News

Dimed SA Distribuidora de Medicamentos (BSP:PNVL3) Q4 2025 Earnings Call Highlights: Record ...

Dimed SA Distribuidora de Medicamentos (BSP:PNVL3) Q4 2025 Earnings Call Highlights: Record Growth and Strategic Challenges

5 weeks ago - GuruFocus

Q4 2025 Dimed SA Distribuidora de Medicamentos Earnings Call Transcript

5 weeks ago - GuruFocus

Dimed S.A. Distribuidora de Medicamentos Earnings Call Transcript: Q3 2025

Q3 2025 saw strong sales growth of 14.3%, robust digital expansion, and a 32.6% rise in private label sales. EBITDA and cash flow improved, while net income was impacted by higher interest rates. The outlook remains positive, with continued focus on digital, private label, and generics.

6 months ago - Transcripts

Dimed S.A. Distribuidora de Medicamentos Earnings Call Transcript: Q2 2025

Q2 2025 saw nearly 20% sales growth, strong EBITDA and net income gains, and continued market share expansion, driven by digital, private label, and store expansion strategies. Positive trends are expected to continue, with further margin improvements and growth in key categories.

9 months ago - Transcripts

Dimed S.A. Distribuidora de Medicamentos Earnings Call Transcript: Q1 2025

Q1 2025 saw 15.9% sales growth, stable 29.4% retail gross margin, and 7% EBITDA growth, driven by mature store productivity, digital expansion, and private label gains. Market share increased for the 20th consecutive quarter, with strong cash flow and low leverage.

1 year ago - Transcripts

Q3 2024 Dimed SA Distribuidora de Medicamentos Earnings Call Transcript

1 year ago - GuruFocus